Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CytRx
ClinicalTrials.gov Identifier:
NCT01706835
First received: October 11, 2012
Last updated: December 15, 2014
Last verified: December 2014
History of Changes

October 11, 2012
December 15, 2014
October 2012
December 2014   (final data collection date for primary outcome measure)
Pharmacokinetics [ Time Frame: up to 3 months ] [ Designated as safety issue: No ]
Blood samples will be obtained for pharmacokinetics. Standard pharmacokinetic parameters, including t1/2, Cmax, AUC, Vd and CL, will be determined.
Same as current
Complete list of historical versions of study NCT01706835 on ClinicalTrials.gov Archive Site
Safety [ Time Frame: up to 6 months ] [ Designated as safety issue: Yes ]

All subjects who receive any amount of aldoxorubicin will be included in the safety analyses, which will include the following:

  1. The incidence, severity, duration, causality, seriousness, and type of AEs and changes in the subject's physical examination, vital signs, and clinical laboratory results.
  2. Deaths and other SAEs will be tabulated.
Same as current
Not Provided
Not Provided
 
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
This is a phase 1 open-label study to investigate the pharmacokinetics of aldoxorubicin administered as a 30 minute infustion every 3 weeks for up to 8 cycles in subjects with advanced solid tumors.
An Open-Label Phase 1 Study to Investigate the Pharmacokinetics of Aldoxorubicin Administered as a 30 Minute Infusion Every 3 Weeks in Subjects with Advanced Solid Tumors.
Interventional
Phase 1
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Solid Tumors
Drug: aldoxorubicin
Other Name: INNO-206
Experimental: Aldoxorubicin
Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.
Intervention: Drug: aldoxorubicin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age ≥18 years, male or female.
  2. Histologically or cytologically confirmed malignant solid tumor that has relapsed or is refractory to standard therapy.
  3. Subjects who have received prior radiation therapy with stable central nervous system (CNS) metastasis with no progression of brain metastasis by CT/MRI scan in last 4 weeks.
  4. Capable of providing informed consent and complying with trial procedures.
  5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
  6. Life expectancy >12 weeks.
  7. Measurable or evaluable disease.
  8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. [Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.].
  9. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
  10. Geographic accessibility to the site.

Exclusion Criteria:

  1. Palliative surgery, chemotherapy, immunotherapy and/or radiation treatment less than 4 weeks prior to the Screening Visit.
  2. Exposure to any investigational agent within 30 days of the Screening Visit.
  3. Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or 5 times the ULN in liver metastases, total bilirubin greater than 3 times the ULN, white blood cell (WBC) count <3500/mm3, absolute neutrophil (ANC) count < 2000/mm3, platelet concentration <100,000/mm3, hematocrit level <25% for females or <28% for males (transfusion is allowed during screening).
  4. Clinically evident congestive heart failure (CHF) > class II of the New York Heart Association (NYHA) guidelines.
  5. Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.
  6. Recent history (within 6 months) or current signs of active coronary artery disease with or without angina pectoris.
  7. Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram) or ultrasound determined absolute left ventricular ejection fraction (LVEF) <45% of predicted.
  8. Known history of HIV infection.
  9. Active, clinically significant serious infection requiring treatment with antibiotics, antivirals or antifungals.
  10. Major surgery within 4 weeks prior to treatment.
  11. Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.
  12. Any condition that is unstable and could jeopardize the subject's participation in the study.
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01706835
ALDOXORUBICIN-P1-PK-01
No
Not Provided
Not Provided
CytRx
CytRx
Not Provided
Study Director: Dan Levitt, MD CytRx Coorporation
CytRx
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP